South Korea

Campaign launched with video featuring Jang Won-Young away from her glamorous stage image in quiet, everyday moments to reflect the brand's philosophy, "When Skin Heals, You Bloom."

SamChunDang Pharmaceutical has penned an exclusive licensing and commercialization agreement covering generic versions of oral semaglutide products in the UK and additional European markets.

A decade ago, China was buying Western drugs. Now it is selling them. Executives who ignore the shift do so at their peril.

The Korean player plans to expand its biosimilar portfolio to more than 40 products by 2038, while advancing late-stage candidates including a streamlined Phase III trial of its secukinumab biosimilar.

With the separation from its parent company now behind it, Samsung Bioepis celebrated its highest-ever annual revenues and outlined its vision of further growth.

A deal for the Duchenne muscular dystrophy treatment with Nxera is valued at up to $205m.

Generics Bulletin reviews global regulatory developments across the world.

European Commission approval positions Celltrion to streamline hospital workflows, with modelling suggesting millions in potential annual savings for healthcare systems.

Juby Jacob-Nara outlines her vision for expanding biosimilar uptake and leveraging policy changes to improve patient access.

Hikma has picked up the commercialization rights to half-a-dozen Celltrion biosimilars in the Middle East and North Africa, in the latest agreement between the pair.

Evaluate data show three biopharma initial public offerings on Western stock exchanges in the third quarter, up from two in Q2, all in the US. But China shows similar IPO activity.

With the looming spin-off on the horizon, Samsung Bioepis looks at planned product launches and geographic expansion to maintain its annual revenue growth.